Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.

Date publication

mars 2021

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33684552

Résumé

Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We summarize efficacy and safety data of tofacitinib 5 or 10 mg twice daily (BID) in the UC clinical program, stratified by prior tumor necrosis factor inhibitor (TNFi) failure status.

Mots clés

JAK inhibitor, adverse events of special interest, inflammatory bowel disease, tumor necrosis factor antagonist

Référence

Clin Gastroenterol Hepatol. 2021 Mar 5;: